Ph II Cabazitaxel DD Liposarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Dedifferentiated Liposarcoma
Interventions
DRUG

Cabazitaxel

Trial Locations (11)

21079

CHU de Dijon - Centre Georges-Francois-Leclerc (229), Dijon

Unknown

Universitair Ziekenhuis Antwerpen (117), Antwerp

Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet (101), Brussels

Centre Leon Berard (227), Lyon

Assistance Publique - Hopitaux de Marseille - Hôpital de La Timone (287), Marseille

Fondazione IRCCS Istituto Nazionale dei Tumori (704), Milan

Istituto Oncologico Veneto IRCCS - Ospedale Busonera (3908), Padua

Clatterbridge Centre for Oncology NHS Trust - Clatterbridge Cancer Centre NHS Foundation Trust (659), Bebington

Royal Marsden Hospital - Chelsea, London (613), London

The Christie NHS Foundation Trust (610), Manchester

EH4 2XU

Western General Hospital, Edinburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT01913652 - Ph II Cabazitaxel DD Liposarcoma | Biotech Hunter | Biotech Hunter